Agencies, 13 November: Bharat Biotech’s COVID dawai COVAXIN te 77.8 percent efficacy toh Phase-III trials data te COVID-19 symptomatic kelaaf dekhise. Data toh medical journal The Lancet te November 12, 2021 te publish kora thakise. Bharat Biotech para November 2020 te COVAXIN laga Phase-III trials janaideya thakise. Etu toh India laga first aro sobse dangor Phase-III efficacy trials thakise.
COVACIN laga Phase-III trial Efficacy aro Safety data publish kora toh Word Health Organization (WHO) para November 3, 2021 te Emergency Use Listing (EUL) mana bechite ase.
The Lancet te COVAXIN laga Phase-III trials date dekhaideya:
Severe symptomatic COVID-19 kelaaf 93.4 per cent efficacy.
symptomatic COVID-19 kelaaf 77.8 per cent efficacy.
Asymptomatic COVID-19 kelaaf 63.6 per cent efficacy.
Delta variant of COVID-19 kelaaf 65.2 per cent efficacy.
Kappa variant of COVID-19 kelaaf 90.1 per cent efficacy.
COVID-19 laga sob variants kelaaf 70.8 percent efficacy.
Add Comment